The Clinical Characteristics and Prognosis of Chinese Early Stage Breast Cancer Patients: A Retrospective Study

医学 乳腺癌 阶段(地层学) 内科学 肿瘤科 回顾性队列研究 癌症 生物 古生物学
作者
Wen L Lu,Hai X Li,Bi Yun Qian,Yuan Wang,Liesbeth Jansen,Guo Wei Huang,Nai-jun Tang,Zhong Sun,Kexin Chen,Geertruida H. de Bock
出处
期刊:Breast Journal [Wiley]
卷期号:16 (3): 331-333 被引量:11
标识
DOI:10.1111/j.1524-4741.2010.00903.x
摘要

To the Editor: Despite the lower incidence of breast cancer in China, the absolute number of new cases is high because of large population (there are 1.31 billion inhabitants). Of the new cases of breast cancer in the world, 21.3% are diagnosed in China. In addition, cancer registries in China do record annual increases in incidence of 3–4%, which is higher than in other countries (1). There is no nationwide breast screening program in China because of relatively lower breast cancer incidence and resource constraint. In contrast to Western countries, breast conservation therapy is uncommon and most of the patients receive mastectomy along with more widespread use of adjuvant therapy. Given these differences, we evaluated the clinical characteristics and prognosis of breast cancer in China. A random selection was made of 1,197 records out of 5,987 patients diagnosed with breast cancer. For 1,086 patients, baseline information was available (see Table 1); for 830 patients 5-year follow-up information was available (see Table 2). The median age at diagnosis of patients was 48.0 years (range: 19–80 years), and 431 (39.7%) women were older than 50. In contrast, the median age of diagnosis of breast cancer is higher in European Countries and the United States (median: 58–63) (2,3). These differences cannot be explained by differences in life-expectancy, as there are only small differences in life-expectancy between China (about 75), Korea (about 82), and Western Countries (about 79–83) (4). These differences can also not be explained by the absence of a nation wide screening program, as in Western countries without screening program the median age at diagnosis of breast cancer is about 60 (3). In a multi-ethnic cohort study, the breast cancer risk of Asian postmenopausal women appeared to be comparable to American women after adjusting for the risk factors, such as overweight and alcohol consumption (5). It seems reasonable to hypothesize that environmental factors play a role. The patients in our study had more advanced stages of breast cancer than those in the United States and European studies. The pathologic stage was T1 and T2 in 814 (75.0%) patients; 475 patients (43.7%) were in pathologic stage N0. The possible explanation might be the absence of a nationwide breast cancer screening program in China, whereas such programs are fully or partly implemented in majority of developed countries (6). A minority of women (n = 44, 4.1%) received breast conserving treatment and all of these patients with specified stage information 31 (70.5%) were in stage I and stage II. Besides 95 (48.0%) stage III patients, 23 (22.5%) stage I and 264 (38.4%) stage II patients received neo-adjuvant chemotherapy. A majority of women received post-treatment adjuvant therapy, with 588 (54.1%) receiving radiation therapy, 896 (82.5%) receiving adjuvant chemotherapy, and 374 (34.4%) receiving endocrine therapy; 497 out of 1041 patients (47.7%) received mastectomy combined with radiation therapy and chemotherapy. Of the 475 patients with N0 stage, 230 (48.4%) patients received radiation therapy, and 382 (80.4%) patients received adjuvant chemotherapy. Of the 102 patients with stage I tumors, 81 (79.4%) patients received mastectomy, and 36 (44.4%) patients received mastectomy as well as radiotherapy. In 683 patients with stage II tumors, 580 patients received mastectomy, and 354 (61.0%) patients received mastectomy as well as radiotherapy. Breast conservation therapy was uncommon in China until the late 1990s even in those areas with more westernized culture because of the relatively small breast size of Chinese women and uncertainty about the long-term clinical and cosmetic outcome in this ethic group. Mastectomy was still widely perceived as the only curative treatment for Chinese women (7). Furthermore, the adjuvant therapies were accepted widely. The more aggressive treatment strategies are carried out after taking into account the patients' preferences, financial status, and knowledge. Despite the unfavorable primary tumor status, the patients in our study showed a good disease-free survival and overall survival, being 84% and 88% at 5 years, and 77% and 83% at 10 years, respectively. This was comparable to survival data from the United States and Europe (2,3). The end point evaluated was death from any cause in this study, so the competing risk should be taken into consideration because the patients in western countries are at higher risk of dying from other causes than older age. The incidence of relapse was smaller as compared with some other studies (4% versus 4–9%) (8–10). Five-year cumulative incidences of loco-regional recurrence and contra-lateral recurrence were 2.9% (95% CI: 1.9–3.9) and 0.7% (95% CI: 0.2–1.2), respectively. The combination of mastectomy with systemic adjuvant radiotherapy and chemotherapy in our hospital was a reasonable explanation for the lower incidence of loco-regional recurrence. There might be some other genetic and environmental factors needed to be clarified. In summary, breast cancer patients in our series had more advanced tumor stages and were given more aggressive treatment. Despite this, the clinical outcome was comparable to Western countries and less relapse was found. Our findings indicate that more aggressive treatment is acceptable in those areas without routine breast screening program.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
我想@科研发布了新的文献求助10
刚刚
MHX发布了新的文献求助10
刚刚
衿霜发布了新的文献求助10
刚刚
sxm发布了新的文献求助10
1秒前
2秒前
大端发布了新的文献求助10
2秒前
王小姐不吃药完成签到 ,获得积分10
2秒前
2秒前
领导范儿应助孟双采纳,获得10
2秒前
iNk应助合适尔槐采纳,获得20
3秒前
5秒前
单薄飞莲完成签到,获得积分10
5秒前
Crystal发布了新的文献求助10
5秒前
量子星尘发布了新的文献求助10
6秒前
Jasper应助漂流的云朵采纳,获得10
6秒前
7秒前
ding应助呆呆熊采纳,获得10
7秒前
背后飞柏完成签到,获得积分10
8秒前
8秒前
麦丰完成签到,获得积分10
8秒前
澈哩发布了新的文献求助10
8秒前
gg发布了新的文献求助10
9秒前
小鱼饼完成签到,获得积分10
9秒前
balabala发布了新的文献求助10
9秒前
m31发布了新的文献求助10
10秒前
DX发布了新的文献求助30
10秒前
10秒前
10秒前
独孤骄子完成签到 ,获得积分0
10秒前
11秒前
替我活着发布了新的文献求助10
11秒前
能干亦云发布了新的文献求助400
11秒前
ZZZ发布了新的文献求助10
11秒前
11秒前
淘气科研完成签到,获得积分10
12秒前
科研小狗完成签到,获得积分10
12秒前
13秒前
13秒前
Owen应助和和采纳,获得10
14秒前
15秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970949
求助须知:如何正确求助?哪些是违规求助? 3515634
关于积分的说明 11179061
捐赠科研通 3250769
什么是DOI,文献DOI怎么找? 1795474
邀请新用户注册赠送积分活动 875831
科研通“疑难数据库(出版商)”最低求助积分说明 805188